324 related articles for article (PubMed ID: 25530110)
1. Permissive expansion and homing of adoptively transferred T cells in tumor-bearing hosts.
Perez C; Jukica A; Listopad JJ; Anders K; Kühl AA; Loddenkemper C; Blankenstein T; Charo J
Int J Cancer; 2015 Jul; 137(2):359-71. PubMed ID: 25530110
[TBL] [Abstract][Full Text] [Related]
2. Visualizing the dynamic of adoptively transferred T cells during the rejection of large established tumors.
Charo J; Perez C; Buschow C; Jukica A; Czeh M; Blankenstein T
Eur J Immunol; 2011 Nov; 41(11):3187-97. PubMed ID: 21898380
[TBL] [Abstract][Full Text] [Related]
3. A Transgenic Dual-Luciferase Reporter Mouse for Longitudinal and Functional Monitoring of T Cells
Szyska M; Herda S; Althoff S; Heimann A; Russ J; D'Abundo D; Dang TM; Durieux I; Dörken B; Blankenstein T; Na IK
Cancer Immunol Res; 2018 Jan; 6(1):110-120. PubMed ID: 29259004
[TBL] [Abstract][Full Text] [Related]
4. Adoptive immunotherapy with tumor-specific T lymphocytes generated from cytokine gene-modified tumor-primed lymph node cells.
Ohno K; Yoshizawa H; Tsukada H; Takeda T; Yamaguchi Y; Ichikawa K; Maruyama Y; Suzuki Y; Suzuki E; Arakawa M
J Immunol; 1996 May; 156(10):3875-81. PubMed ID: 8621926
[TBL] [Abstract][Full Text] [Related]
5. Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer.
Moon EK; Ranganathan R; Eruslanov E; Kim S; Newick K; O'Brien S; Lo A; Liu X; Zhao Y; Albelda SM
Clin Cancer Res; 2016 Jan; 22(2):436-47. PubMed ID: 26324743
[TBL] [Abstract][Full Text] [Related]
6. Dendritic cell internalization of α-galactosylceramide from CD8 T cells induces potent antitumor CD8 T-cell responses.
Choi DH; Kim KS; Yang SH; Chung DH; Song B; Sprent J; Cho JH; Sung YC
Cancer Res; 2011 Dec; 71(24):7442-51. PubMed ID: 22028323
[TBL] [Abstract][Full Text] [Related]
7. Adoptively transferred tumor-specific T cells stimulated ex vivo using herpes simplex virus amplicons encoding 4-1BBL persist in the host and show antitumor activity in vivo.
Yi KH; Nechushtan H; Bowers WJ; Walker GR; Zhang Y; Pham DG; Podack ER; Federoff HJ; Tolba KA; Rosenblatt JD
Cancer Res; 2007 Oct; 67(20):10027-37. PubMed ID: 17942937
[TBL] [Abstract][Full Text] [Related]
8. Engineering T cells for adoptive therapy: outsmarting the tumor.
Kunert A; Debets R
Curr Opin Immunol; 2018 Apr; 51():133-139. PubMed ID: 29579622
[TBL] [Abstract][Full Text] [Related]
9. Monitoring the efficacy of adoptively transferred prostate cancer-targeted human T lymphocytes with PET and bioluminescence imaging.
Dobrenkov K; Olszewska M; Likar Y; Shenker L; Gunset G; Cai S; Pillarsetty N; Hricak H; Sadelain M; Ponomarev V
J Nucl Med; 2008 Jul; 49(7):1162-70. PubMed ID: 18552144
[TBL] [Abstract][Full Text] [Related]
10. Efficient eradication of subcutaneous but not of autochthonous gastric tumors by adoptive T cell transfer in an SV40 T antigen mouse model.
Bourquin C; von der Borch P; Zoglmeier C; Anz D; Sandholzer N; Suhartha N; Wurzenberger C; Denzel A; Kammerer R; Zimmermann W; Endres S
J Immunol; 2010 Aug; 185(4):2580-8. PubMed ID: 20644173
[TBL] [Abstract][Full Text] [Related]
11. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
[TBL] [Abstract][Full Text] [Related]
12. Different lineages of P1A-expressing cancer cells use divergent modes of immune evasion for T-cell adoptive therapy.
Bai XF; Liu JQ; Joshi PS; Wang L; Yin L; Labanowska J; Heerema N; Zheng P; Liu Y
Cancer Res; 2006 Aug; 66(16):8241-9. PubMed ID: 16912204
[TBL] [Abstract][Full Text] [Related]
13. Rapid Construction of Antitumor T-cell Receptor Vectors from Frozen Tumors for Engineered T-cell Therapy.
Tsuji T; Yoneda A; Matsuzaki J; Miliotto A; Ryan C; Koya RC; Odunsi K
Cancer Immunol Res; 2018 May; 6(5):594-604. PubMed ID: 29588318
[TBL] [Abstract][Full Text] [Related]
14. Blocking TCR restimulation induced necroptosis in adoptively transferred T cells improves tumor control.
Kesarwani P; Chakraborty P; Gudi R; Chatterjee S; Scurti G; Toth K; Simms P; Husain M; Armeson K; Husain S; Garrett-Mayer E; Vasu C; Nishimura MI; Mehrotra S
Oncotarget; 2016 Oct; 7(43):69371-69383. PubMed ID: 27750220
[TBL] [Abstract][Full Text] [Related]
15. IND-Enabling Studies for a Clinical Trial to Genetically Program a Persistent Cancer-Targeted Immune System.
Puig-Saus C; Parisi G; Garcia-Diaz A; Krystofinski PE; Sandoval S; Zhang R; Champhekar AS; McCabe J; Cheung-Lau GC; Truong NA; Vega-Crespo A; Komenan MDS; Pang J; Macabali MH; Saco JD; Goodwin JL; Bolon B; Seet CS; Montel-Hagen A; Crooks GM; Hollis RP; Campo-Fernandez B; Bischof D; Cornetta K; Gschweng EH; Adelson C; Nguyen A; Yang L; Witte ON; Baltimore D; Comin-Anduix B; Kohn DB; Wang X; Cabrera P; Kaplan-Lefko PJ; Berent-Maoz B; Ribas A
Clin Cancer Res; 2019 Feb; 25(3):1000-1011. PubMed ID: 30409823
[TBL] [Abstract][Full Text] [Related]
16. Human T cells engineered to express a programmed death 1/28 costimulatory retargeting molecule display enhanced antitumor activity.
Ankri C; Shamalov K; Horovitz-Fried M; Mauer S; Cohen CJ
J Immunol; 2013 Oct; 191(8):4121-9. PubMed ID: 24026081
[TBL] [Abstract][Full Text] [Related]
17. Targeted elimination of prostate cancer by genetically directed human T lymphocytes.
Gade TP; Hassen W; Santos E; Gunset G; Saudemont A; Gong MC; Brentjens R; Zhong XS; Stephan M; Stefanski J; Lyddane C; Osborne JR; Buchanan IM; Hall SJ; Heston WD; Rivière I; Larson SM; Koutcher JA; Sadelain M
Cancer Res; 2005 Oct; 65(19):9080-8. PubMed ID: 16204083
[TBL] [Abstract][Full Text] [Related]
18. T-cell receptor gene therapy targeting melanoma-associated antigen-A4 inhibits human tumor growth in non-obese diabetic/SCID/γcnull mice.
Shirakura Y; Mizuno Y; Wang L; Imai N; Amaike C; Sato E; Ito M; Nukaya I; Mineno J; Takesako K; Ikeda H; Shiku H
Cancer Sci; 2012 Jan; 103(1):17-25. PubMed ID: 21951605
[TBL] [Abstract][Full Text] [Related]
19. Cancer immunotherapy with lymphocytes genetically engineered with T cell receptors for solid cancers.
Chen L; Qiao D; Wang J; Tian G; Wang M
Immunol Lett; 2019 Dec; 216():51-62. PubMed ID: 31597088
[TBL] [Abstract][Full Text] [Related]
20. Synergistic effect of lymphotactin and interferon gamma-inducible protein-10 transgene expression in T-cell localization and adoptive T-cell therapy of tumors.
Huang H; Xiang J
Int J Cancer; 2004 May; 109(6):817-25. PubMed ID: 15027114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
